<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454024</url>
  </required_header>
  <id_info>
    <org_study_id>NOPEN3-3882</org_study_id>
    <secondary_id>U1111-1116-2517</secondary_id>
    <nct_id>NCT01454024</nct_id>
  </id_info>
  <brief_title>Evaluating Safety of NovoPen® 3 and/or FlexPen® Devices in Routine Clinical Practice</brief_title>
  <official_title>A Study Evaluating the Safety of NovoPen®3 and FlexPen® in Subjects With Type 1 and Type 2 Diabetes. A 24-week, Prospective, Multi-centre, Open-labelled, Non-interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Asia. The aim of of this study is to evaluate the safety of
      NovoPen® 3 and/or FlexPen® devices (if available on the market) measured by the number of
      adverse events and technical complaints in patients with type 1 and type 2 diabetes in
      routine clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events and technical complaints</measure>
    <time_frame>Week 0-24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse drug reactions (ADR) including hypoglycaemic events</measure>
    <time_frame>Week 0-12, week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse drug reactions including major hypoglycaemic events</measure>
    <time_frame>Week 0-12, week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c (haemoglobin A1c)</measure>
    <time_frame>Week 0, week 12 and week 24</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1031</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Delivery Systems</condition>
  <arm_group>
    <arm_group_label>Total study population</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FlexPen®</intervention_name>
    <description>Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice</description>
    <arm_group_label>Total study population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovoPen® 3</intervention_name>
    <description>Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice</description>
    <arm_group_label>Total study population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The selection of the subjects will be at the discretion of the individual physician based
        on clinical judgement.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any subjects who are previously using Actrapid®, Insulatard®, and Mixtard® 30 with
             vial / NovoLet® or insulin human with ErgoPen®2 for type 1 and type 2 diabetes
             treatment, will be eligible for the study after the physician has taken the decision
             to use study insulin products with the study devices

        Exclusion Criteria:

          -  Subjects treated with Actrapid® Penfill®, Insulatard® Penfill®, or Mixtard® 30
             Penfill® with NovoPen®3 or Actrapid® FlexPen®, Insulatard® FlexPen®, or Mixtard® 30
             FlexPen® for more than 4 weeks before inclusion into this study

          -  Subjects who were previously enrolled in this study

          -  Subjects with a hypersensitivity to insulin human or to any of the excipients

          -  Women who are pregnant, breast feeding or have the intention of becoming pregnant
             within the next 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>October 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2011</study_first_posted>
  <last_update_submitted>June 11, 2015</last_update_submitted>
  <last_update_submitted_qc>June 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

